2156-56-1 Usage
Description
Sodium dichloroacetate (DCA) is a white powder chemical compound that functions as a mitochondrial pyruvate dehydrogenase kinase (PDK) inhibitor. It is an orally absorbable small molecular compound known for its potent anti-leukemic activity and potential therapeutic applications in various diseases.
Uses
Used in Neurologic Injury Treatment:
Sodium dichloroacetate is used as a pyruvate dehydrogenase activator for the treatment of neurologic injury. It aids in the activation of pyruvate dehydrogenase, which is crucial for the conversion of pyruvate to acetyl-CoA, a key process in cellular energy production.
Used in MELAS Syndrome and Congenital Lactic Acidosis Treatment:
Sodium dichloroacetate is used as an orally absorbable small molecular compound for the treatment of MELAS syndrome, congenital lactic acidosis, and other related diseases. It helps in managing the symptoms and improving the quality of life for patients with these conditions.
Used in Cardiovascular Applications:
Sodium dichloroacetate acts as a potential vasoprotective agent by inhibiting PDK2 and reducing coronary endarterium proliferation. This suggests its potential use in the prevention and treatment of cardiovascular diseases.
Used in Brain Regeneration:
Recent studies have found that DCA promotes brain regeneration after cerebral ischemia, indicating its potential role in the treatment of conditions related to brain damage and stroke.
Used in Pharmaceutical Industry:
Sodium dichloroacetate, under the brand name Ceresine (Cypros), is used in the pharmaceutical industry for the development of drugs targeting various diseases, including cancer and neurologic disorders.
Biological Activity
Inhibitor of mitochondrial pyruvate dehydrogenase kinase (PDK). Shifts pyruvate metabolism from glycolysis and lactate production to glucose oxidation in the mitochondria. Induces mitochondrial-dependent apoptosis and reverses the inhibition/downregulation of K V 1.5 channels in cancer but not normal cells. Decreases tumor growth in vitro and in vivo .
Check Digit Verification of cas no
The CAS Registry Mumber 2156-56-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,1,5 and 6 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 2156-56:
(6*2)+(5*1)+(4*5)+(3*6)+(2*5)+(1*6)=71
71 % 10 = 1
So 2156-56-1 is a valid CAS Registry Number.
InChI:InChI=1/C2H2Cl2O2.Na/c3-1(4)2(5)6;/h1H,(H,5,6);/q;+1/p-1
2156-56-1Relevant articles and documents
Structural analogues of quinoline alkaloids: Straightforward route to [1,3]dioxolo[4,5-c]quinolines with antibacterial properties
?am?ulová, Veronika,Funk, Petr,Grepl, Martin,Horák, Radim,Hradil, Pavel,Ko?istek, Kamil,Kvapil, Lubomír,Slaninová, Ludmila,Soural, Miroslav
, (2020/02/04)
Compounds bearing [1,3]dioxolo-quinoline scaffolds have been found in quinoline-based natural products; the only exception is the [1,3]dioxolo[4,5-c]quinoline moiety with a rare occurrence in both natural and synthetic derivatives. In this article, we report the preparation of diversely substituted and functionalized [1,3]dioxolo[4,5-c]quinolines using [1,3]dioxolo[4,5-c]quinoline-4-carbaldehyde (DQC) as the common intermediate. DQC was synthesized on a large scale from anthranilic acid and chloroacetone as the starting materials, with the rearrangement of acetonyl-anthranilate as the key step. The developed method allows for the simple preparation of [1,3]dioxolo[4,5-c]quinolines with various C2 substituents on the quinoline scaffold. Additionally, the synthetic route was successfully applied to the preparation of 3-hydroxyquinoline-4(1H)-ones. The target compounds were tested against representative Gram-positive/negative bacteria, and two derivatives exhibited submicromolar minimum inhibitory concentrations against Micrococcus luteus.